.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ06_Semaglutide.Semaglutide .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ06_Semaglutide.Semaglutide| name: | Semaglutide |
| ATC code: | A10BJ06 | route: | subcutaneous |
| n-compartments | 2 |
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of type 2 diabetes mellitus and chronic weight management. It is currently approved for clinical use in both oral and subcutaneous injectable formulations.
Pharmacokinetic parameters reported for healthy subjects and patients with type 2 diabetes (predominantly adults), after subcutaneous administration.
Overgaard, RV, et al., & Ingwersen, SH (2019). Population Pharmacokinetics of Semaglutide for Type 2 Diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders 10(2) 649–662. DOI:10.1007/s13300-019-0581-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/30788808
Yang, XD, & Yang, YY (2024). Clinical Pharmacokinetics of Semaglutide: A Systematic Review. Drug design, development and therapy 18 2555–2570. DOI:10.2147/DDDT.S470826 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38952487
Overgaard, RV, et al., & Kildemoes, RJ (2021). Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clinical pharmacokinetics 60(10) 1335–1348. DOI:10.1007/s40262-021-01025-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/33969456